Tumor Markers for Follow-Up of Thyroid Carcinoma

  • Chr. Reiners
Conference paper


Malignant epithelial tumors of the thyroid can be characterized oncologically on the basis of some special features (Table 1). For the follow-up, it is very important that most of these tumors secrete hormones or hormone precursors which may serve as very specific tumor markers. Because of the generally good prognosis (the anaplastic type excluded), the number of patients who have to be followed-up increases continuously despite the relative rareness of thyroid malignancies (approx. 40 new cases/year in our department). On the other hand, malignant thyroid tumors not seldom metastasize after several years of uncomplicated course. Therefore, the diagnostic program for follow-up requires sensitive, specific, and cost-effective methods which do not bother the patient. Depending on the histological type of thyroid carcinoma, determinations of different tumor markers can fulfill these criteria.


Thyroid Cancer Thyroid Carcinoma Medullary Thyroid Carcinoma Differentiate Thyroid Cancer Differentiate Thyroid Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ashcraft MW, Van Herle AJ (1981) The comparative value of serum thyroglobulin measurements and Iodine-131 total body scans in the follow-up study of patients with treated thyroid cancer. Am J Med 71:806–814PubMedCrossRefGoogle Scholar
  2. 2.
    Bayer M, McDougall R (1984) Differences in radioimmunoassay results for thyroglobulin that affect management of patients with thyroid cancer. Clin Chem 30:81–86PubMedGoogle Scholar
  3. 3.
    Black EG, Hoffenberg R (1983) Should one measure serum thyroglobulin in the presence of anti-thyroglobulin antibodies? Clin Endocrinol (Oxf) 19:597–601CrossRefGoogle Scholar
  4. 4.
    Botsch H (1982) Radioimmunoassay fur die Serum-Thyreoglobulinbestimmung. Klinische Anwendung als Tumormarker bei der Verlaufskontrolle des differenzierten Schilddrüsenkarzinoms. Thieme, StuttgartGoogle Scholar
  5. 5.
    Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E (1984) Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53:278–285PubMedCrossRefGoogle Scholar
  6. 6.
    Castagnoli A, Cappelli G, D’Agata A, Forni S, Milani S, Pupi A (1982) Can thyroglobulin assay really supplant radioiodine scans in patients with differentiated thyroid cancer? Lancet 573Google Scholar
  7. 7.
    Charles MA, Dodson LE, Waldeck N, Hofeldt F, Ghaed N, Telepak R, Ownbey J, Burstein PH (1980) Serum thyroglobulin levels predict total body iodine scan findings in patients with treated well-differentiated thyroid carcinoma. Am J Med 69:401–407PubMedCrossRefGoogle Scholar
  8. 8.
    Colacchio THA, Lo Gerfo P, Colacchio DA, Feind C (1982) Radioiodine total body scan versus serum thyroglobulin levels in follow-up of patients with thyroid cancer. Surgery 91:42–45PubMedGoogle Scholar
  9. 9.
    Deftos LJ (1974) Radioimmunoassay for calcitonin in medullary thyroid carcinoma. JAMA 227:403–406PubMedCrossRefGoogle Scholar
  10. 10.
    Echenique RL, Kasi L, Haynie TP, Glenn HJ, Samaan NA, Stratton Hill C (1982) Critical evaluation of serum thyroglobulin levels and I-131 scans in post-therapy patients with differentiated thyroid carcinoma: Concise communication. J Nucl Med 23:235–240PubMedGoogle Scholar
  11. 11.
    Feldt-Rasmussen U, Holten I, Sand Hansen A (1983) Influence of thyroid substitution therapy and thyroid autoantibodies on the value of serum thyroglobulin in recurring thyroid cancer. Cancer 51:2240–2243PubMedCrossRefGoogle Scholar
  12. 12.
    Hennesy JF, Wells SA, Ontjes DA, Cooper GW (1974) A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J Clin Endocrinol 39:487–495CrossRefGoogle Scholar
  13. 13.
    Hüfner M, Stumpf HP, Grussendorf M, Hermann HJ, Kimmig B (1982) The significance of whole body scanning and plasma thyroglobulin measurements in the follow-up of metastatic thyroid cancer. Acta Endocrinol (Copenh) [Suppl] 246:59–60Google Scholar
  14. 14.
    Hüfner M, Stumpf HP, Hermann HJ, Kimmig B (1983) Diagnostischer Wert des J-131- Ganzkörperszintigramms in der Nachsorge des differenzierten Schilddrüsenkarzinoms. Dtsch Med Wochenschr 108:1234–1238PubMedCrossRefGoogle Scholar
  15. 15.
    Jänsch A, Heinze HG, Hast B (1981) Serum-Thyreoglobulin (S-hTg). Ein Tumormarker bei Patienten mit differenziertem Schilddrüsenkarzinom. Strahlentherapie 157:381–392PubMedGoogle Scholar
  16. 16.
    Martino E, Bambini G, Aghini-Lombardi F, Motz E, Pacini F, Lari R, Baschier L, Pinchera A (1984) Serum tissue polypeptide antigen (TPA) in thyroid cancer. J Endocrinol Invest 7:249–252PubMedGoogle Scholar
  17. 17.
    McDougall IR, Bayer MF (1980) Follow-up of patients with differentiated thyroid cancer using serum thyroglobulin measured by an immunoradiometric assay. Comparison with I-131 total body scans. J Nucl Med 21:741–744PubMedGoogle Scholar
  18. 18.
    Mendelsohn G, Wells SA, Baylin SB (1984) Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized and virulent disseminated stages of disease. Cancer 54:657–662PubMedCrossRefGoogle Scholar
  19. 19.
    Moser E, Braun S, Kirsch CM, Kleinhans E, Buell U (1984) Time course of thyroglobulin autoantibodies in patients with differentiated thyroid carcinoma after radioiodine therapy. Nucl Med Commun 5:317–321PubMedCrossRefGoogle Scholar
  20. 20.
    Oehr P, Vogel J, Lichius A, Selbach B, Biersack HJ, Winkler C, Gedigk P (1984) Vorkommen und Bedeutung von Thyreoglobulin, Tissue Polypeptide Antigen, Carcinoembryonalem Antigen und Calcitonin in Geweben und im Plasma von Schilddrüsenkarzinom-Patienten. Tumor Diagn 5:129–138Google Scholar
  21. 21.
    Pacini F, Pinchera A, Giani C, Grasso L, Baschieri L (1980) Serum thyroglobulin concentrations and 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin Endocrinol (Oxf) 13:107–110CrossRefGoogle Scholar
  22. 22.
    Reiners CHR (1981) Spezifìsche und unspezifîsche Tumormarker beim Schilddrüsenkarzinom. Simultane Bestimmung von Thyreoglobulin, Kalzitonin, Carcinoembryonalem Antigen, Alpha-Foetoprotein, Beta-Choriongonadotropin, Tissue Polypeptide Antigen, Immunoglobulin E, Ferritin und Tennessee Antigen. Tumor Diagn 2:199–208Google Scholar
  23. 23.
    Reiners CHR (1983) Serum thyroglobulin as a substitution of I-131-scans in follow-up of differentiated thyroid cancer? Act Endocrinol (Copenh) [Suppl] 252:66–67Google Scholar
  24. 24.
    Reiners CHR (1983) Serum-Thyreoglobulin und Thyreoglobulin-Antikörper. Ergebnisse beim Schilddrüsenkarzinom und anderen Schilddrüsenerkrankungen. Thieme, StuttgartGoogle Scholar
  25. 25.
    Reiners CHR (1984) Klinische Wertigkeit der Thyreoglobulin-Bestimmung im Serum. Akt Endokrinol 5:76–82Google Scholar
  26. 26.
    Reiners CHR, Baum K, Wiedemann W, Schick F, Becker W, Spiegel W, Eilles CHR, Gerhards W, Börner W (1983) Special diagnostics in follow-up of C-cell (medullary)-carcinoma of the thyroid. Act Endocrinol (Copenh) [Suppl] 252:61–62Google Scholar
  27. 27.
    Reiners Chr, Börner W (1982) Ein differenziertes Nachsorgeprogramm für das Schilddrüsenkarzinom. Med Klin 77:34–41Google Scholar
  28. 28.
    Reiners Chr, Börner W, Wiedemann W, Becker W, Schick F, Spiegel W, Eilles CHR, Gerhards W (1982) Kritische Betrachtungen zur diagnostischen Wertigkeit der Thyreoglobulin-Bestimmung beim differenzierten Schilddrüsenkarzinom. In: Höfer R, Bergmann H (eds) Radioaktive Isotope in Klinik und Forschung, vol 15/I. Egermann, Vienna, p 417Google Scholar
  29. 29.
    Reiners CHR, Reimann J, Schaffer R, Baum K, Becker W, Eilles CHR, Gerhards W, Schick F, Spiegel W, Wiedemann W, Börner W (1984) Das metastasierende differenzierte Schilddrüsenkarzinom. Diagnostische Treffsicherheit des Thyreoglobulin-RIA im Vergleich zur J-131 -Ganzkörperszintigraphie. Fortschr Röntgenstr 191:306–313CrossRefGoogle Scholar
  30. 30.
    Reiners CHR, Schramm A (1981) Nachsorge des C-Zell-Karzinoms der Schilddrüse. Ergebnisse der Kalzitoninbestimmung nach selektiver Venenkatheterisierung. MMW 123:1708–1710Google Scholar
  31. 31.
    Schäffer R, Reiners CHR, Reimann J, Börner W (1983) Das onkozytäre Schilddrüsenkarzinom: Klinisch-pathologische Renaissance einer Tumorform? Tumor Diagn 4:161–168Google Scholar
  32. 32.
    Schatz H, Horn W, Grebe SF, Muller H (1983) Thyreoglobulinmessung oder 131Jod-Szintigraphie in der Nachsorge von Patienten mit differenziertem Schilddrüsenkarzinom? Dtsch Med Wochenschr 45:1737–1738Google Scholar
  33. 33.
    Schatz H, Grebe SF, Horn W, Müller H (1984) Nachsorge bei differenziertem Schilddrüsenkarzinom: Serumthyreoglobulinbestimmung statt routinemäβigem J-131-Szintigramm? Wien Klin Wochenschr 96:389–393PubMedGoogle Scholar
  34. 34.
    Schatz H, Grebe S, Mäser E, Teuber J, Horn W, Schröder O, Schatz Ch (1982) Serum- Thyreoglobulinspiegel als Tumormarker bei Schilddrüsenkarzinom. Klin Wochenschr 60:457–464PubMedCrossRefGoogle Scholar
  35. 35.
    Schlumberger M, Charbord P, Fragu P, Lumbroso J, Parmentier C, Tubiana M (1980) Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels. J Clin Endocrinol 51:513–518CrossRefGoogle Scholar
  36. 36.
    Sehlumberger M, Fragu P, Parmentier C, Tubiana M (1981) Thyroglobulin assay in the follow-up of patients with differentiated thyroid carcinomas: comparison of its value in patients with or without normal residual thyroid tissue. Act Endocrinol 98:215–221Google Scholar
  37. 37.
    Schneider AB, Line BR, Goldman JM, Robbins J (1981) Sequential serum thyroglobulin determinations, 131I scans, and 131I uptake after triodothyronine withdrawal in patients with thyroid cancer. J Clin Endocrinol 53:1199–1206CrossRefGoogle Scholar
  38. 38.
    Stumpf HP, Hüfner M, Hermann HJ, Kimmig B (1984) Langzeitbeobachtung bei 15 Patienten mit differenziertem Schilddrüsenkarzinom und unklar erhöhten Plasmathyreoglobulinspiegeln (Tg). Klin Wochenschr 62:417–422PubMedCrossRefGoogle Scholar
  39. 39.
    Van Herle AJ, Uller RP (1975) Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinoma. J Clin Invest 56:272–277PubMedCrossRefGoogle Scholar
  40. 40.
    Weissel M, Bergmann H, Höfer R (1980) Klinische Wertigkeit von Serumthyreoglobulinund J-131-Ganzkörperretentionsmessungen bei der Metastasensuche von differenzierten Schilddrüsenkarzinomen. Act Med Austriaca 7:114–119Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • Chr. Reiners
    • 1
  1. 1.Abteilung für NuklearmedizinUniversität WürzburgWürzburgGermany

Personalised recommendations